Top Markets
Coin of the day
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Peringkat dalam Saham #16435
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Harga Saham
$3.12
Kapitalisasi Pasar
$294.21M
Perubahan (1 hari)
-3.26%
Perubahan (1 tahun)
-51.10%
Negara
US
Perdagangan Myriad Genetics, Inc. (MYGN)

Kategori

Harga MYGN dengan kapitalisasi pasar B
Myriad Genetics, Inc. Myriad Genetics, Inc.
MYGN
$3.12
Kapitalisasi pasar dari Myriad Genetics, Inc.(MYGN)
Kapitalisasi Pasar: $294.21M
Per September 2026, Myriad Genetics, Inc. memiliki kapitalisasi pasar sebesar $294.21M. Ini menjadikan Myriad Genetics, Inc. sebagai perusahaan 16435th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Myriad Genetics, Inc. dari 1995 hingga 2026
MYGN dibandingkan dengan 5 teratas stocks paling populer
Harga MYGN Aset B Pasar B Hasil
Myriad Genetics, Inc. Myriad Genetics, Inc.
$55,687.76 $294.21M
$5.260T +1,787,629.19%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$50,594.20 $294.21M
$4.779T +1,624,111.81%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$42,528.50 $294.21M
$4.017T +1,365,181.01%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$39,379.35 $294.21M
$3.719T +1,264,084.73%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$28,949.62 $294.21M
$2.734T +929,261.77%